🇺🇸 FDA
Patent

US 7354581

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

granted A61KA61K31/138A61K31/355

Quick answer

US patent 7354581 (Therapeutic combination of a VEGF antagonist and anti-hypertensive agent) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/138, A61K31/355, A61K31/401, A61K31/403